Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.

[1]  S. Rajkumar,et al.  Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance , 2009, Clinical Cancer Research.

[2]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[3]  T. Espevik,et al.  Toll-like receptors mediate proliferation and survival of multiple myeloma cells , 2006, Leukemia.

[4]  A. Dispenzieri,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[5]  Alex S. Morton,et al.  Discrete time modelling of disease incidence time series by using Markov chain Monte Carlo methods , 2005 .

[6]  Isabelle Bray,et al.  Application of Markov chain Monte Carlo methods to projecting cancer incidence and mortality , 2002 .

[7]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[8]  Niels Keiding,et al.  Age‐Specific Incidence and Prevalence: A Statistical Perspective , 1991 .

[9]  M. C. Leske,et al.  Estimating incidence from age-specific prevalence for irreversible diseases with differential mortality. , 1986, Statistics in medicine.

[10]  Stefan Sperlich,et al.  Generalized Additive Models , 2014 .

[11]  R. Kyle,et al.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. , 1978, The American journal of medicine.

[12]  T. E. Harris,et al.  The Theory of Branching Processes. , 1963 .

[13]  R A Kyle,et al.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2009, Leukemia.

[14]  Susan A. Murphy,et al.  Monographs on statistics and applied probability , 1990 .